Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Recruiting

Phase 2

FrexalimabEfficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Sponsor:

Sanofi

Code:

NCT05039840

Conditions

Systemic Lupus Erythematosus

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

SAR441344 IV

SAR441344 SC

Placebo IV

Placebo SC

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Sanofi on 2025-04-16.